智通财经APP讯，昊海生物科技(06826)发布公告，该公司于2025年12月22日斥资43.49万港元回购1.7万 股股份，每股回购价格为25.54-25.6港元。 ...

翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 上海昊海生物科技股份有限公司（於中華人民共和國註冊成立的股份有限公司） FF305 呈交日期： 2025年12月22日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 06826 | 說明 | H 股 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份） ...

Core Viewpoint - Haohai Biological Technology (688366.SH) plans to acquire approximately 8.466 million shares of Jiangxi Ruiji Biological Engineering Technology Co., Ltd. (Ruiji Bio), representing 19.8% of Ruiji Bio's total share capital, for about 38.35 million yuan, raising concerns among investors due to the absence of performance commitments or earn-out arrangements [1][4]. Group 1: Acquisition Details - The acquisition is aimed at enhancing Haohai's product portfolio and business resilience, as well as laying the groundwork for the development of innovative material products [3]. - The total valuation of Ruiji Bio in this transaction is approximately 194 million yuan, which reflects a significant premium over its net asset value of several tens of millions [3]. - Haohai will become the sixth largest shareholder of Ruiji Bio after the acquisition, with its major shareholder, You Jie, already holding a significant stake in Ruiji Bio [5][6]. Group 2: Financial Performance of Ruiji Bio - Ruiji Bio has been operating at a loss, with a net profit of approximately -1.18 million yuan in 2024 and -1.13 million yuan in the first three quarters of 2025, indicating a trend of declining financial performance [4][8]. - The company's total assets were about 98.89 million yuan in 2024, with total liabilities of approximately 11.20 million yuan, leading to a net asset value of around 87.69 million yuan [4]. - The revenue for Ruiji Bio was approximately 46.36 million yuan in 2024, with a similar revenue figure of about 46.09 million yuan reported for the first three quarters of 2025, suggesting stagnation in sales [4]. Group 3: Market Context and Strategic Implications - The acquisition allows Haohai to enter the high-value medical device market, specifically in the field of biological amniotic membranes, which are used in orthopedic and ophthalmic applications [7]. - Haohai's recent acquisition of the remaining 20% stake in Shenzhen New Industry Ophthalmology Technology Co., Ltd. indicates a strategic focus on enhancing its presence in the ophthalmic high-value consumables sector [7]. - The company has faced declining revenues across its core business segments, with a reported 7.12% decrease in revenue year-on-year for the first half of the year, driven by factors such as insufficient domestic demand and price competition [8].

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 上海昊海生物科技股份有限公司（於中華人民共和國註冊成立的股份有限公司） 呈交日期： 2025年12月19日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 06826 | 說明 H 股 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 ...

（原标题：昊海生物科技(06826)12月19日斥资28.88万港元回购1.13万股） 智通财经APP讯，昊海生物科技(06826)发布公告，该公司于2025年12月19日斥资28.88万港元回购1.13万 股股份，每股回购价格为25.54-25.56港元。 ...

昊海生物科技(06826)发布公告，该公司于2025年12月19日斥资28.88万港元回购1.13万股股份，每股回 购价格为25.54-25.56港元。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 上海昊海生物科技股份有限公司（於中華人民共和國註冊成立的股份有限公司） 呈交日期： 2025年12月19日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 06826 | 說明 H 股 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 ...

Group 1 - The article reports on share buybacks conducted by various companies on December 18, 2025, with Tencent Holdings leading in both the number of shares repurchased and the total amount spent [1] - Tencent Holdings repurchased 1.055 million shares for a total of 636 million yuan, representing 1.030% of its total share capital for the year [2] - Other notable companies involved in the buyback include Xiaomi Group, which repurchased 3.75 million shares for 151 million yuan, and China National Petroleum Corporation, which repurchased 254,000 shares for 116.38 million yuan [3] Group 2 - The total number of shares repurchased by companies varied significantly, with China National Petroleum Corporation having a cumulative buyback of 230 million shares, which is 0.190% of its total share capital [3] - Companies like IGG and VITASOY also participated, with IGG repurchasing 182,000 shares for 68.49 million yuan and VITASOY repurchasing 122,000 shares for 77.94 million yuan [3] - The buyback activity reflects a strategic move by these companies to enhance shareholder value and manage their capital structure effectively [1][2]

热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 客户端 热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 客户端 责任编辑：卢昱君 香港联交所最新数据显示，12月16日，执行董事兼财务负责人唐敏捷增持昊海生物科技（06826）1万 股，每股作价24.86港元，总金额约为24.86万港元。增持后最新持股数目约为3.54万股，最新持股比例 为0.09%。 责任编辑：卢昱君 香港联交所最新数据显示，12月16日，执行董事兼财务负责人唐敏捷增持昊海生物科技（06826）1万 股，每股作价24.86港元，总金额约为24.86万港元。增持后最新持股数目约为3.54万股，最新持股比例 为0.09%。 ...

香港联交所最新数据显示，12月16日，执行董事兼财务负责人唐敏捷增持昊海生物科技(06826)1万股， 每股作价24.86港元，总金额约为24.86万港元。增持后最新持股数目约为3.54万股，最新持股比例为 0.09%。 ...